Close

SIRION Biotech and Vibalogics partner to offer complete Adeno-Associated Virus (AAV) services

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...
- Advertisement -

SIRION Biotech GmbH and Vibalogics GmbH, have signed a strategic partnership agreement designed to meet demand from gene therapy companies for a start-to-finish Adeno-Associated Virus (AAV) service.

The new service offering, which will be available from the beginning of 2018, will allow the two companies to cater to virtually all customer needs for viral vector services, from initial vector engineering and development to GMP production.

As part of the collaboration, SIRION Biotech will provide specialist AAV technology, while Vibalogics will act as its production partner for customers ready to progress to clinical trials.

Dr. Christian Thirion, CTO and founder of SIRION Biotech said: “This step will allow us to offer one of the most versatile and complete AAV services packages in the world and meet demand for a more streamlined development and supply process. We are looking forward to a partnership that will empower gene therapy companies to make sure that ingenious new treatments get to the patient without delay.”

Along with the expanded service offering, the companies will also establish new stringent quality levels for pre-clinical virus batches that will emulate Vibalogics’ GMP production methods. This strategy will ensure that pre-clinical research can be conducted with fully scalable products at ‘GMP-like’ quality, while maintaining cost and time efficiency.

Dr. Stefan Beyer, Managing Director of Vibalogics said: “We are delighted to enter into this partnership and be in a position to offer our customers a broader service than we can offer alone. We believe that this is a great opportunity for companies in the AAV field to benefit from a seamless transition from pre-clinical activities to clinical manufacturing.”

SIRION Biotech, based in Munich, is a virus engineering expert specialising in viral vector technologies. Using its team of specialists and expertise in the biotech industry, the company carries out complex development projects to customize AAV dynamics and improve vector tropisms, safety and productivity.

Vibalogics, based in Cuxhaven, Germany, offers GMP manufacturing and development services for the biopharmaceutical industry and specialises in the handling and manufacture of viruses and live bacterial products for therapeutic and prophylactic applications. The company is one of the few providers of GMP compliant fill and finish services dealing with live viruses and bacteria. In addition to GMP manufacturing, Vibalogics offers process development, assay development and release testing services along with QP release of the clinical batch to complete the chain of activities.

contact:
Lindsay Baldry ramarketing
lindsay@ramarketingpr.com
0191 222 1242
ramarketingpr.com

SIRION Biotech GmbH
Am Klopferspitz 19
82152 Martinsried/Planegg
Germany
+49 89 700 961 99 9
info@sirion-biotech.com
www.sirion-biotech.com

Vibalogics GmbH
Zeppelinstraße 2
27472 Cuxhaven
Germany
+49 4721 565 400
contact@vibalogics.com

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »